The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of dalpiciclib plus fulvestrant and pyrotinib in HR+, HER2-low advanced breast cancer following CDK4/6 inhibitor and aromatase inhibitor: A Bayesian optimal phase ? trial.
 
Chunfang Hao
No Relationships to Disclose
 
Jing Shi
No Relationships to Disclose
 
Yuhua Song
No Relationships to Disclose
 
Jie Ma
No Relationships to Disclose
 
Hua Yang
No Relationships to Disclose
 
Yongsheng Jia
No Relationships to Disclose
 
Cuiping Song
No Relationships to Disclose
 
Wenjing Meng
No Relationships to Disclose
 
Jie Zhang
No Relationships to Disclose